Scarica l'app Stockscreener
66.38
1.35%
-0.91
Dopo l'orario di chiusura:
66.70
0.32
+0.48%
10 X Genomics Inc Borsa (TXG) Ultime notizie
10x Genomics to Use Lunit’s AI-Powered Pathology Platform for Oncology Biomarker Discovery - GenomeWeb
AI will pair tissue scans with molecular maps in cancer studies - Stock Titan
10x genomics director Stuelpnagel sells $1.2 million in shares By Investing.com - Investing.com Australia
symbol__ Stock Quote Price and Forecast - CNN
10x Genomics (NASDAQ: TXG) executive plans multimillion-dollar stock sale - Stock Titan
10x Genomics stock hits 52-week high at 66.95 USD By Investing.com - Investing.com South Africa
Macrogen to offer 10x Genomics spatial biology platform in Asia first - Korea Biomedical Review
10x genomics director Stuelpnagel sells $1.2 million in shares - Investing.com
10x Genomics Inc (TXG) Stock Up 4.7% but GF Value Says Overvalued -- GF Score: 56/100 - GuruFocus
10x Genomics (TXG) director offloads 20,000 shares in open-market trades - Stock Titan
T. Rowe Price reports 10%+ holding in 10x Genomics (TXG) - Stock Titan
Stifel reiterates Buy rating on 10X Genomics stock - Investing.com
10X Genomics Inc (TXG) Key Financial Ratios – Valuation, Profitability & More - Value Research
10x Genomics (TXG) CEO holds 1,075,249 shares after 100-share gift - Stock Titan
Founder trust at 10x Genomics (NASDAQ: TXG) moves to sell 20,000 shares - Stock Titan
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead? - Yahoo Finance
TXG Stock Price and Chart — NASDAQ:TXG - TradingView
A Look at 10x Genomics Inc (TXG) After 4.0% Decline -- GF Value $18.36 vs Price $60.00 - GuruFocus
RBC Capital initiates 10X Genomics stock with Sector Perform rating - Investing.com
10X GENOMICS, INC. : RBC INITIATES COVERAGE WITH SECTOR PERFORM RATING; TARGET PRICE $70 - Bitget
Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit - Benzinga
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences - TradingView
10x Genomics Wins Patent Infringement Verdict against Parse Biosciences - marketscreener.com
Delaware jury finds Parse infringed three genetic-sequencing patents - Reuters
10x Genomics Inc (TXG) Shares Fall 5.1% -- GF Value Says Still O - GuruFocus
10x Genomics (TXG) CEO sells 10,486 shares under 10b5-1 plan - Stock Titan
10x Genomics wins jury award in Qiagen patent row (TXG:NASDAQ) - Seeking Alpha
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences - Porterville Recorder
10x Genomics Inc (TXG) Director Shehnaaz Suliman Sells 2,207 Sha - GuruFocus
10x Genomics (NASDAQ: TXG) CEO sells for taxes, still holds 1,085,835 shares - Stock Titan
10x Genomics (NASDAQ: TXG) CEO lines up another share sale - Stock Titan
10x Genomics (NASDAQ: TXG) exec to sell 16,614 shares - Stock Titan
10x Genomics (NASDAQ: TXG) insider plans sale of 17,948 shares - Stock Titan
10x Genomics (NASDAQ: TXG) holder to sell about $871K in stock - Stock Titan
10x Genomics (TXG) CEO gifts 4,000 shares in stock donation - Stock Titan
10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade) (TXG) - Seeking Alpha
Fed. Circ. Backs PTAB's Ax Of 10x Genomics Patent Claims - law360.com
Federal Circuit Upholds PTAB Obviousness Rulings Against Single Cell Sequencing Patents - IPWatchdog.com
10x Genomics Gains as Investors Extend Post-Earnings Rally on Atera Demand - Quiver Quantitative
10x Genomics’ Bid to Revive Patents Rejected by Federal Circuit - Bloomberg Law News
10x Genomics (NASDAQ:TXG) Reaches New 52-Week HighWhat's Next? - MarketBeat
10x Genomics stock hits 52-week high at $60.73 By Investing.com - Investing.com Australia
10x Genomics stock hits 52-week high at $60.73 - Investing.com
Bank of America Corp DE Has $20.48 Million Position in 10x Genomics $TXG - MarketBeat
Director Sarah Teichmann Sells 7,551 Shares of 10x Genomics Inc (TXG) - GuruFocus
10x Genomics (TXG) Sees Strong Early Orders for New Atera Platform - Yahoo Finance
A Look at 10x Genomics Inc (TXG) After 3.4% Gain -- GF Value $18 - GuruFocus
10x Genomics Inc (TXG) (Q2 2026) Earnings Call Highlights: Atera Launch Drives Record Demand Amidst Transition - GuruFocus
10x Genomics (NASDAQ: TXG) director sells under 10b5-1 plan - Stock Titan
7 Best Genomics Stocks for 2026 and How to Invest - The Motley Fool
10x Genomics (TXG) Could Be 35% Above Fair Value Following 2026 Outlook Lift - Yahoo Finance
10x Genomics (TXG) Dips 3.5% to $56.09 as Support at $53.29 Comes Into ViewTrend Reversal Picks - Vinanet
5 Revealing Analyst Questions From 10x Genomics’s Q2 Earnings Call - Yahoo Finance
Cathie Wood’s ARK sells 10X Genomics stock, buys Perceptive Capital By Investing.com - Investing.com Canada
Cathie Wood’s ARK sells 10X Genomics stock, buys Perceptive Capital - Investing.com
A Look at 10x Genomics Inc (TXG) After 3.6% Decline -- GF Value $18.38 vs Price $56.09 - GuruFocus
TXG (TXG) insider schedules sale of common stock and notes prior sale - Stock Titan
ARK Investment Management (TXG) reports 10.0M-share position in 10x Genomics - Stock Titan
10x Genomics, Inc.: Financial Data Forecasts Estimates and Expectations | TXG | US88025U1097 - marketscreener.com
10x Genomics director John Stuelpnagel sells $1.15m in shares - Investing.com
10x Genomics director John Stuelpnagel sells $1.15m in shares By Investing.com - Investing.com Australia
10x Genomics Director John R. Stuelpnagel Sells 20,000 Shares in August 2026 SEC Filing - Kalkine Media
Insider Selling: 10x Genomics (NASDAQ:TXG) Director Sells 20,000 Shares of Stock - MarketBeat
2.04%
3.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):